Pharmazz, Inc.
Pharmazz is a privately held company developing novel products in critical care medicine. The U.S. Food and Drug Administration (FDA) has approved two phase III INDs for Centhaquine as an agent for hypovolemic shock and Sovateltide for cerebral ischemic stroke.
4
Funding Rounds
$24.0m
Money raised
Overview
Pharmazz is a privately held company developing novel products in critical care medicine. The U.S. Food and Drug Administration (FDA) has approved two phase III INDs for Centhaquine as an agent for hypovolemic shock and Sovateltide for cerebral ischemic stroke.
Funding series
Funding Series Analysis
The company Pharmazz, Inc. has raised a total of $15m in funding over 4 rounds.
Key Insights:
- Pharmazz, Inc August 2024 Corporate Round Funding round: $15m
- Pharmazz, Inc. funding round, March 2020: $5m
- Pharmazz, Inc. funding round, August 2019: $3m
- Pharmazz, Inc. funding round, January 2018: $1m
Pharmazz, Inc August 2024 Corporate Round Funding round
$15m
Pharmazz, Inc. funding round, March 2020
$5m
Pharmazz, Inc. funding round, August 2019
$3m
Pharmazz, Inc. funding round, January 2018
$1m
Industries
Pharmazz, Inc. is active in the following industries: